ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.497,94
-0,09%
S&P 500
5.277,51
0,80%
Dow Jones
38.686,32
1,51%
Euro vs US Dollar
1,08565
-0,01%
Bitcoin
67.627,07
0,22%
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Pharvaris NV (PHVS)

  7. Pharvaris NV (PHVS) News

PHVS

Pharvaris NV (PHVS)

Pharvaris NV
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:PHVS
DatumZeitQuelleÜberschriftSymbolFirma
24/05/202423h04Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:PHVSPharvaris NV
22/05/202423h54Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:PHVSPharvaris NV
13/05/202412h50GlobeNewswire Inc.Pharvaris to Present Clinical and Nonclinical Data at Upcoming CongressesNASDAQ:PHVSPharvaris NV
08/05/202422h11Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHVSPharvaris NV
08/05/202422h10GlobeNewswire Inc.Pharvaris Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:PHVSPharvaris NV
10/04/202422h10GlobeNewswire Inc.Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:PHVSPharvaris NV
10/04/202422h08GlobeNewswire Inc.Pharvaris Appoints David Nassif, J.D., as Chief Financial OfficerNASDAQ:PHVSPharvaris NV
04/04/202412h50GlobeNewswire Inc.Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 ConferenceNASDAQ:PHVSPharvaris NV
18/03/202411h50GlobeNewswire Inc.Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE CongressesNASDAQ:PHVSPharvaris NV
11/03/202418h51Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:PHVSPharvaris NV
06/03/202422h40Edgar (US Regulatory)Form F-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:PHVSPharvaris NV
06/03/202422h15Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHVSPharvaris NV
06/03/202412h50GlobeNewswire Inc.Pharvaris to Present Deucrictibant Clinical Data at Upcoming CongressesNASDAQ:PHVSPharvaris NV
05/03/202412h50GlobeNewswire Inc.Pharvaris to Participate in the Leerink Global Biopharma Conference 2024NASDAQ:PHVSPharvaris NV
22/02/202412h50GlobeNewswire Inc.Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual MeetingNASDAQ:PHVSPharvaris NV
16/02/202412h51Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHVSPharvaris NV
16/02/202412h50GlobeNewswire Inc.Pharvaris Announces Extraordinary Meeting of ShareholdersNASDAQ:PHVSPharvaris NV
07/02/202422h01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHVSPharvaris NV
01/02/202422h46Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:PHVSPharvaris NV
26/01/202412h50GlobeNewswire Inc.Pharvaris to Present at the WSAAI Annual Meeting 2024NASDAQ:PHVSPharvaris NV
22/01/202413h35Dow Jones NewsPharvaris Says FDA Lifted Clinical Hold on Application for DeucrictibantNASDAQ:PHVSPharvaris NV
22/01/202412h51Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHVSPharvaris NV
22/01/202412h50GlobeNewswire Inc.Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE AttacksNASDAQ:PHVSPharvaris NV
08/01/202413h00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHVSPharvaris NV
05/01/202412h50GlobeNewswire Inc.Pharvaris Provides Business Update and Outlines 2024 Strategic PrioritiesNASDAQ:PHVSPharvaris NV
02/01/202422h29Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:PHVSPharvaris NV
09/12/202300h00GlobeNewswire Inc.Pharvaris Presents Deucrictibant Clinical Data and Analysis of Endpoints for Trials of On-demand Treatment of HAE at the GA²LEN UCARE Conference 2023NASDAQ:PHVSPharvaris NV
08/12/202322h50Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHVSPharvaris NV
07/12/202322h17Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:PHVSPharvaris NV
06/12/202322h36Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:PHVSPharvaris NV
 Showing the most relevant articles for your search:NASDAQ:PHVS

Kürzlich von Ihnen besucht

NASDAQ
PTHR
Pono Capital Three
USOTC
GAMGF
Gamelancer Media (QB)
AQEU
BCM
Brunello Cucinelli
AQSE
INC
Incanthera
GDAX
TIAUSD
Celestia
USOTC
GEODF
Geodrill (QX)
TG
M11
First Graphene
LSE
0W9P
TG
KEE
Keyence
USOTC
IGPG
Ignis Petroleum (CE)
AMEX
RJMG
FT Raymond James Multica...
EU
ACLU
Axa IM ETF ICAV
TG
3AI
Alteryx
EU
9439T
9439T
TG
W8N
AquaBounty Technologies
COIN
BTKKBTC
Bitcoin Token
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten